Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Interest & Investment Income (2016 - 2025)

Editas Medicine (EDIT) has disclosed Interest & Investment Income for 11 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 48.13% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.8 million, a 56.38% decrease, with the full-year FY2024 number at $14.1 million, down 19.95% from a year prior.
  • Interest & Investment Income was $1.8 million for Q3 2025 at Editas Medicine, down from $2.1 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $5.1 million in Q3 2023 to a low of $134000.0 in Q1 2021.
  • A 5-year average of $2.3 million and a median of $2.1 million in 2025 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 91.4% in 2021, then skyrocketed 1449.71% in 2022.
  • Editas Medicine's Interest & Investment Income stood at $175000.0 in 2021, then surged by 1449.71% to $2.7 million in 2022, then surged by 88.13% to $5.1 million in 2023, then plummeted by 76.46% to $1.2 million in 2024, then soared by 52.46% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Interest & Investment Income are $1.8 million (Q3 2025), $2.1 million (Q2 2025), and $2.7 million (Q1 2025).